126 related articles for article (PubMed ID: 22592429)
1. Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease.
Blanco-García R; Bravo-López JJ; Moreiras-Plaza M; Nájera-de la Garza W; Cossio-Annibar C; Beato-Coo L; Rodríguez-Goyanes G
Nefrologia; 2012 May; 32(3):401-2. PubMed ID: 22592429
[No Abstract] [Full Text] [Related]
2. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
[TBL] [Abstract][Full Text] [Related]
3. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.
Hervás Sánchez JG; Prados Garrido MD; Polo Moyano A; Cerezo Morales S
Nefrologia; 2011; 31(6):697-706. PubMed ID: 22130286
[TBL] [Abstract][Full Text] [Related]
5. Severe secondary hyperparathyroidism.
Foerster D; Chmielewski C
Nephrol Nurs J; 2001 Dec; 28(6):647-8. PubMed ID: 12143475
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
Staniforth ME; Cheng SC; Coyne DW
Clin Nephrol; 2005 Jun; 63(6):454-60. PubMed ID: 15960147
[TBL] [Abstract][Full Text] [Related]
7. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients.
Coronel F; Rodríguez-Cubillo B; Cigarrán S; Gomis A
Adv Perit Dial; 2011; 27():130-3. PubMed ID: 22073844
[TBL] [Abstract][Full Text] [Related]
9. [Parathyroidectomy in secondary hyperparathyroidism in chronic uremic patients under dialysis treatment. Development of the surgical strategy].
Zucchi C
Minerva Med; 1985 Mar; 76(9-10):397-401. PubMed ID: 3982697
[No Abstract] [Full Text] [Related]
10. Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis.
Noertersheuser PA; Pradhan RS; Klein CE; Williams LA; Palaparthy R; Garimella TS; Lichtenberger O; Awni WM
J Clin Pharmacol; 2012 Aug; 52(8):1162-73. PubMed ID: 21940716
[TBL] [Abstract][Full Text] [Related]
11. Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol.
Kant KS; Gonzalez AR; Hariachar S; Bernardo M; Duggal A; Engstrand S; Hunter J; Plone M; Hertel J
J Ren Nutr; 2012 Jan; 22(1):34-40.e2. PubMed ID: 21652220
[TBL] [Abstract][Full Text] [Related]
12. Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up.
Shuja SB; Raja RM
Adv Perit Dial; 2003; 19():231-5. PubMed ID: 14763069
[TBL] [Abstract][Full Text] [Related]
13. Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients.
Drüeke TB; Landais P
Am J Kidney Dis; 2006 Jun; 47(6):1083; author reply 1083-4. PubMed ID: 16731305
[No Abstract] [Full Text] [Related]
14. Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.
Kida Y
N Engl J Med; 2003 Nov; 349(20):1971-2; author reply 1971-2. PubMed ID: 14626256
[No Abstract] [Full Text] [Related]
15. Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.
Mansour J; Shahapuni I; Mailliez S; Aghai R; Fournier A
Nat Clin Pract Nephrol; 2007 Apr; 3(4):E2; discussion E3. PubMed ID: 17389886
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
Webb NJA; Lerner G; Warady BA; Dell KM; Greenbaum LA; Ariceta G; Hoppe B; Linde P; Lee HJ; Eldred A; Dufek MB
Pediatr Nephrol; 2017 Jul; 32(7):1221-1232. PubMed ID: 28332096
[TBL] [Abstract][Full Text] [Related]
17. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis.
Drüeke TB; McCarron DA
N Engl J Med; 2003 Jul; 349(5):496-9. PubMed ID: 12890849
[No Abstract] [Full Text] [Related]
18. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
Teng M; Wolf M; Lowrie E; Ofsthun N; Lazarus JM; Thadhani R
N Engl J Med; 2003 Jul; 349(5):446-56. PubMed ID: 12890843
[TBL] [Abstract][Full Text] [Related]
19. Effect of calcium-channel blockers on calcium-phosphate metabolism in patients with end-stage renal disease.
Lippuner K; Zehnder HJ; Casez JP; Takkinen R; Descoeudres C; Jaeger P
Nephrol Dial Transplant; 1996 Jan; 11(1):70-4. PubMed ID: 8649655
[TBL] [Abstract][Full Text] [Related]
20. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol.
Hernandez JD; Wesseling K; Boechat MI; Gales B; Salusky IB
Nat Clin Pract Nephrol; 2007 Apr; 3(4):227-32. PubMed ID: 17389892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
